Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antitumor agent or postoperative adjuvant chemotherapeutic agent for treatment of hepatocellular carcinoma

A technology of hepatocellular carcinoma and antineoplastic agents, applied in the fields of antineoplastic agents, organic chemistry, digestive system, etc., can solve problems such as unestablished treatment methods and unestablished effectiveness of adjuvant chemotherapy methods, achieve excellent therapeutic effects and worsen survival Prolonged duration and high therapeutic effect

Inactive Publication Date: 2012-11-14
TAIHO PHARMA CO LTD
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] As mentioned above, for the treatment system of hepatocellular carcinoma, the treatment method that can be used as standard therapy has not yet been established, and the effectiveness of adjuvant chemotherapy after TAE has not been established. medicine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antitumor agent or postoperative adjuvant chemotherapeutic agent for treatment of hepatocellular carcinoma
  • Antitumor agent or postoperative adjuvant chemotherapeutic agent for treatment of hepatocellular carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0060] Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.

[0061] TSU-68 therapy for hepatocellular carcinoma patients after TACE

[0062] A comparison between the TSU-68-administered group and the non-administered group was performed for those patients who were unable to adapt to liver resection and percutaneous local therapy but were treated with TACE, excluding cases whose liver reserve function was diagnosed as C by Child-pugh classification. Clinical Trials. Here, the antitumor agent used in TACE is epirubicin.

[0063] Subject cases were randomly assigned to TSU-68 administration group and non-administration group. The cases assigned to the TSU-68 administration group started administration of TSU-68 within 2 weeks after the implementation of TACE. The administration of TSU-68 was 200 mg once, and it was orally administered twice a day after breakfast and after d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is an antitumor agent or postoperative adjuvant chemotherapeutic agent for a hepatocellular carcinoma patient who underwent transarterial embolization. Specifically disclosed is an antitumor agent or a postoperative adjuvant chemotherapeutic agent, which contains TSU-68 or a salt thereof and can be administered to a hepatocellular carcinoma patient, who has undergone transarterial embolization, within two weeks after the operation.

Description

technical field [0001] The present invention relates to an antitumor agent or an adjuvant chemotherapeutic agent after surgery for the treatment of hepatocellular carcinoma patients after hepatic artery embolization. Specifically, it relates to an antitumor agent or an adjuvant chemotherapeutic agent that can be administered to a patient with hepatocellular carcinoma after hepatic artery embolization operation within 2 weeks after the operation. Background technique [0002] Treatment methods for hepatocellular carcinoma include surgical resection, hepatic artery embolization (hereinafter referred to as "TAE"), percutaneous topical therapy (percutaneous ethanol infusion therapy, percutaneous radio wave cautery, etc.), chemotherapy, radiotherapy, liver transplantation and other methods. TAE is a surgical treatment method for selectively inducing hepatocellular carcinoma necrosis by injecting an embolic substance such as gelatin sponge into the hepatic artery of a patient wit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/404A61P35/00C07D403/06
CPCC07D403/06A61K31/404A61P1/16A61P35/00
Inventor 冈俊范
Owner TAIHO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com